Condensed Consolidated Financial Statement Details (Tables)

3 Months Ended

Mar. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):

	March 31, 2023		December 31, 2022
Raw materials	$	2,234	$	2,575
Work-in-process	13,167		10,749
Finished goods	4,834		5,878
Total inventory	$	20,235	$	19,202

Schedule of Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

	March 31, 2023		December 31, 2022
Building and leasehold improvements	$	69,137	$	74,889
Computer equipment and computer software	24,894		26,205
Manufacturing equipment	25,339		25,052
Laboratory equipment	13,566		24,243
Furniture, fixtures and other	3,990		4,263
Depreciable property, plant and equipment at cost	136,926		154,652
Less: accumulated depreciation	(110,653)		(124,731)
Depreciable property, plant and equipment, net	26,273		29,921
Construction in process	811		2,530
Property, plant and equipment, net	$	27,084	$	32,451

Schedule of Goodwill

The following is a reconciliation of the changes in our goodwill for the three months ended March 31, 2023 (in thousands):

	Three months ended March 31, 2023
Goodwill – beginning balance	$	76,501
Impairment of goodwill	(76,501)
Goodwill – ending balance	$	—

Schedule of Liability Related to Sale of Potential Future Royalties

The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the three months ended March 31, 2023 (in thousands):

	Three Months Ended March 31, 2023
	2012 Purchase and Sale Agreement		2020 Purchase and Sale Agreement		Total
Liabilities related to the sales of future royalties, net – beginning balance	$	55,167	$	100,211	$	155,378
Non-cash royalty revenue	(9,303)		(7,558)		(16,861)
Non-cash interest expense	1,360		5,045		6,405
Amortization of transaction costs	—		209		209
Liabilities related to the sales of future royalties, net – ending balance	$	47,224	$	97,907	$	145,131

Schedule of Accrued Expenses

Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31, 2023		December 31, 2022
Accrued compensation	$	14,888	$	9,582
Accrued clinical trial expenses	7,739		12,262
Liability to collaboration partners	3,495		3,808
Accrued contract termination costs	3,461		3,902
Other accrued expenses	7,827		7,003
Total accrued expenses	$	37,410	$	36,557